SCHEMBL1974203

SCHEMBL1974203

CCCCOC(=O)c1nc(Cl)c2ccsc2c1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.45
LMNA P02545 4/20 0.45
MAPT P10636 3/20 0.45
ATM Q13315 2/20 0.45
GAA P10253 1/20 0.45
ESR1 P03372 8/20 0.44
TSHR P16473 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2D6 P10635 1/20 0.41
MAPK1 P28482 1/20 0.41
NR1H2 P55055 1/20 0.41
RNASEL Q05823 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
COMT P21964 1/20 0.39
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
PDE4D Q08499 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1972674 0.91 L3MBTL1 (0.45) L3MBTL1LMNAMAPTATMGAA
SCHEMBL1975712 0.88 ESR1 (0.43) L3MBTL1LMNAATMESR1TSHR
SCHEMBL1974100 0.87 ESR1 (0.43) L3MBTL1LMNAATMESR1TSHR
SCHEMBL1973059 0.86 ESR1 (0.44) L3MBTL1LMNAMAPTATMESR1
SCHEMBL1973167 0.83 ESR1 (0.43) L3MBTL1LMNAATMESR1TSHR
SCHEMBL1973669 0.83 ESR1 (0.41) L3MBTL1LMNAMAPTESR1TSHR
SCHEMBL1973776 0.83 EGFR (0.45) L3MBTL1LMNAGAAESR1TSHR
SCHEMBL1974155 0.83 ESR1 (0.39) L3MBTL1LMNAATMESR1TSHR
SCHEMBL1974634 0.82 ESR1 (0.43) L3MBTL1LMNAMAPTATMGAA
SCHEMBL1974320 0.81 MAPT (0.44) L3MBTL1LMNAMAPTGAAESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000006-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2015-04-07 US disclosed
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2014-08-07 US disclosed
US-8703795-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2014-04-22 US disclosed
EP-1866318-B1 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN INC (US) 2011-06-22 EP disclosed
EP-1866318-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2007-12-19 EP disclosed
WO-2006094292-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2006-09-08 WO disclosed
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof FIBROGEN, INC. 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 L3MBTL1 3104/4885LMNA 4317/4885MAPT 3256/4885
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof HIF1AN, HIF1A, EGLN2 L3MBTL1 3104/4885LMNA 4317/4885MAPT 3256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.